Purpose: Micro-UltraSound (microUS) is a new imaging modality capable of identifying and targeting suspicious areas, which might further increase the diagnostic yield of prostate biopsy (PBx). Aim of this review is to provide insights into the usefulness of microUS for the sub-stratification of prostate cancer (PCa), clinically significant PCa (i.e., any Gleason score ≥ 7 PCa; csPCa) along with non-organ-confined disease in patients undergoing PBx.
Methods: A PubMed literature search was performed using keywords: prostate cancer diagnosis, prostate cancer diagnosis surveillance, systematic biopsy, target biopsy, micro-ultrasound, and prostate risk identification using micro-ultrasound.
Results: MicroUS could significantly improve multiparametric magnetic resonance imaging (mpMRI) findings by adding valuable anatomical and pathological information provided by real-time examination. Furthermore, microUS target biopsy could replace systematic biopsy in clinical practice by reducing the detection of clinically insignificant (ciPCa) and increasing that of csPCa. Finally, microUS may be useful in predicting the presence of non-organ confined PCa before radical prostatectomy and it could also be an effective add-on tool for patient monitoring within the active surveillance program.
Conclusion: MicroUS may represent an attractive step forward for the management of csPCa as a complementary or alternative tool to mpMRI. Nevertheless, further longitudinal studies are warranted, and the strength of the evidence is still suboptimal to provide clear recommendations for daily clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00345-023-04521-w | DOI Listing |
Cell Mol Biol (Noisy-le-grand)
January 2025
Al Door Technical Institute, Northern Technical University, Mosul, Iraq.
Prostate cancer is the most common type after the age of fifty. It affects males and affects the prostate gland, which protects the function of sperm by producing semen. The current study was designed to evaluate prostate cancer infection effects on some biomarkers such as irisin, Tumor necrosis factor-TNF-α, prostate acid phosphates -PAP, Glutathione-GSH, malondialdehyde-MDA, urea, and creatinine.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
January 2025
Departamento de Biología Molecular y Genómica y Departamento de Disciplinas Filosófico Metodológicas e Instrumentales. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
ABCG2 transporter protein is one of several markers of prostate cancer stem cells (PCSCs). Gene variants of ABCG2 could affect protein expression, function, or both. The aim of this study was to identify the genetic variability of the ABCG2 gene in Mexican patients with prostate cancer.
View Article and Find Full Text PDFJ Cell Mol Med
January 2025
Department of Medical Biology, Faculty of Medicine, Kutahya Health Sciences University, Kutahya, Turkey.
Chemotherapy is a potent tool against cancer, but drug resistance remains a major obstacle. To combat this, understanding the molecular mechanisms behind resistance in cancer cells and the protein expression changes driving these mechanisms is crucial. Targeting the Ubiquitin-Proteasome System (UPS) has proven effective in treating multiple myeloma and shows promise for solid tumours.
View Article and Find Full Text PDFEur Urol
January 2025
Eastern Health Clinical School, Monash University, Melbourne, Australia; Cancer Services, Eastern Health, Melbourne, Australia; Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Melbourne, Australia.
Eur Urol
January 2025
Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy; "Vita-Salute" San Raffaele University, Milan, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!